MAPT and Alzheimer disease: Immunotherapy targeting Aβ has been demonstrated to modify amyloid [4,5] as well as tau related endpoints [6,7] of AD pathology in pre-clinical models, as well as human clinical trials, and is currently in advanced clinical trials for potential treatment of mild to moderate AD [8,9].